12
Jan
2009
Posted in I - Series A, Q - 1Q09, R - NORTH EAST, X - Oncology, X - Target ID, X - Therapeutic Platform, XX - MA
FORMA Therapeutics (Cambridge, MA) an oncology focused target discovery, screening, structural biology and small molecule developer, closed a $25M Series A funding financing. Participants include Novartis Option Fund and Bio*One Capital.